blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2602261

EP2602261 - BORON COMPOUND WITH AMINO ACID SKELETON CONTAINING CYCLIC RING [Right-click to bookmark this link]
Former [2013/24]BORON COMPOUND WITH AMINO ACID SKELETON CONTAINING CYCLO RING
[2016/16]
StatusNo opposition filed within time limit
Status updated on  18.08.2017
Database last updated on 19.10.2024
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
Stella Pharma Corporation
ORIX Kouraibashi Building 5F 2-7 Kouraibashi 3-chome Chuo-ku
Osaka-shi, Osaka 541-0043 / JP
[2013/30]
Former [2013/24]For all designated states
Stella Pharma Corporation
ORIX Kouraibashi Building 5F 2-7 Kouraibashi 3-chome Chuo-ku
Osaka-shi, Osaka 541-0043 / JP
For all designated states
Osaka Prefecture University Public Corporation
1-1, Gakuencho Naka-ku Sakai-shi
Osaka 599-8531 / JP
Inventor(s)01 / KIRIHATA, Mitsunori
c/o Osaka Prefecture University
1-1 Gakuen-cho
Naka-ku
Sakai-shi Osaka 599-8531 / JP
02 / HATTORI, Yoshihide
c/o Osaka Prefecture University
1-1 Gakuen-cho
Naka-ku
Sakai-shi Osaka 599-8531 / JP
03 / UEHARA, Kohki
c/o STELLA PHARMA CORPORATION
ORIX Kouraibashi Building 5F
2-7 Kouraibashi 3-chome
Chuo-ku
Osaka-shi Osaka 541-0043 / JP
04 / TAKENAKA, Hiroshi
c/o STELLA PHARMA CORPORATION
ORIX Kouraibashi Building 5F
2-7 Kouraibashi 3-chome
Chuo-ku
Osaka-shi Osaka 541-0043 / JP
 [2013/24]
Representative(s)Hart-Davis, Jason, et al
Cabinet Beau de Loménie
158, rue de l'Université
75340 Paris Cedex 07 / FR
[2016/41]
Former [2013/24]Hart-Davis, Jason, et al
Cabinet Beau de Loménie 158, rue de l'Université
75340 Paris Cedex 07 / FR
Application number, filing date11814640.602.08.2011
[2016/41]
WO2011JP67681
Priority number, dateJP2010017453703.08.2010         Original published format: JP 2010174537
[2013/24]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012018015
Date:09.02.2012
Language:JA
[2012/06]
Type: A1 Application with search report 
No.:EP2602261
Date:12.06.2013
Language:EN
[2013/24]
Type: B1 Patent specification 
No.:EP2602261
Date:12.10.2016
Language:EN
[2016/41]
Search report(s)International search report - published on:JP09.02.2012
(Supplementary) European search report - dispatched on:EP28.11.2013
ClassificationIPC:C07F5/02
[2013/24]
CPC:
C07F5/05 (EP,US); A61P31/00 (EP); C07F5/02 (EP,US);
C07F5/027 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/24]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:BORVERBINDUNG MIT EINEM AMINOSÄURESKELETT MIT EINEM ZYKLISCHEN RING[2013/24]
English:BORON COMPOUND WITH AMINO ACID SKELETON CONTAINING CYCLIC RING[2016/16]
French:COMPOSÉ DU BORE À SQUELETTE ACIDE AMINÉ CONTENANT UN NOYAU CYCLIQUE[2016/16]
Former [2013/24]BORON COMPOUND WITH AMINO ACID SKELETON CONTAINING CYCLO RING
Former [2013/24]COMPOSÉ DU BORE À SQUELETTE ACIDE AMINÉ CONTENANT UN NOYAU CYCLO
Entry into regional phase28.02.2013Translation filed 
28.02.2013National basic fee paid 
28.02.2013Search fee paid 
28.02.2013Designation fee(s) paid 
28.02.2013Examination fee paid 
Examination procedure02.05.2012Request for preliminary examination filed
International Preliminary Examining Authority: JP
28.02.2013Examination requested  [2013/24]
23.06.2014Amendment by applicant (claims and/or description)
28.04.2016Communication of intention to grant the patent
30.08.2016Fee for grant paid
30.08.2016Fee for publishing/printing paid
30.08.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  28.04.2016
Opposition(s)13.07.2017No opposition filed within time limit [2017/38]
Fees paidRenewal fee
18.06.2013Renewal fee patent year 03
24.07.2014Renewal fee patent year 04
17.07.2015Renewal fee patent year 05
02.06.2016Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU02.08.2011
AL12.10.2016
AT12.10.2016
BE12.10.2016
CY12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
ES12.10.2016
HR12.10.2016
IT12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
MK12.10.2016
NL12.10.2016
PL12.10.2016
RO12.10.2016
RS12.10.2016
SI12.10.2016
SK12.10.2016
SM12.10.2016
TR12.10.2016
BG12.01.2017
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
[2020/33]
Former [2020/15]HU02.08.2011
AT12.10.2016
BE12.10.2016
CY12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
ES12.10.2016
HR12.10.2016
IT12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
MK12.10.2016
NL12.10.2016
PL12.10.2016
RO12.10.2016
RS12.10.2016
SI12.10.2016
SK12.10.2016
SM12.10.2016
TR12.10.2016
BG12.01.2017
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2019/51]HU02.08.2011
AT12.10.2016
BE12.10.2016
CY12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
ES12.10.2016
HR12.10.2016
IT12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
MK12.10.2016
NL12.10.2016
PL12.10.2016
RO12.10.2016
RS12.10.2016
SI12.10.2016
SK12.10.2016
SM12.10.2016
BG12.01.2017
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2019/46]HU02.08.2011
AT12.10.2016
BE12.10.2016
CY12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
ES12.10.2016
HR12.10.2016
IT12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
NL12.10.2016
PL12.10.2016
RO12.10.2016
RS12.10.2016
SI12.10.2016
SK12.10.2016
SM12.10.2016
BG12.01.2017
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2019/31]HU02.08.2011
AT12.10.2016
BE12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
ES12.10.2016
HR12.10.2016
IT12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
NL12.10.2016
PL12.10.2016
RO12.10.2016
RS12.10.2016
SI12.10.2016
SK12.10.2016
SM12.10.2016
BG12.01.2017
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2018/18]AT12.10.2016
BE12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
ES12.10.2016
HR12.10.2016
IT12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
NL12.10.2016
PL12.10.2016
RO12.10.2016
RS12.10.2016
SI12.10.2016
SK12.10.2016
SM12.10.2016
BG12.01.2017
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/52]AT12.10.2016
BE12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
ES12.10.2016
HR12.10.2016
IT12.10.2016
LT12.10.2016
LV12.10.2016
NL12.10.2016
PL12.10.2016
RO12.10.2016
RS12.10.2016
SI12.10.2016
SK12.10.2016
SM12.10.2016
BG12.01.2017
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/38]AT12.10.2016
BE12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
ES12.10.2016
HR12.10.2016
IT12.10.2016
LT12.10.2016
LV12.10.2016
NL12.10.2016
PL12.10.2016
RO12.10.2016
RS12.10.2016
SK12.10.2016
SM12.10.2016
BG12.01.2017
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/37]AT12.10.2016
BE12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
ES12.10.2016
HR12.10.2016
IT12.10.2016
LT12.10.2016
LV12.10.2016
NL12.10.2016
PL12.10.2016
RO12.10.2016
RS12.10.2016
SK12.10.2016
SM12.10.2016
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/36]AT12.10.2016
BE12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
ES12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
NL12.10.2016
PL12.10.2016
RO12.10.2016
RS12.10.2016
SK12.10.2016
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/34]AT12.10.2016
BE12.10.2016
CZ12.10.2016
DK12.10.2016
ES12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
NL12.10.2016
PL12.10.2016
RS12.10.2016
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/33]AT12.10.2016
BE12.10.2016
DK12.10.2016
ES12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
NL12.10.2016
PL12.10.2016
RS12.10.2016
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/26]AT12.10.2016
BE12.10.2016
ES12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
NL12.10.2016
PL12.10.2016
RS12.10.2016
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/12]LV12.10.2016
Documents cited:Search[Y]WO2010010913  (STELLA PHARMA CORP [JP], et al) [Y] 1-6 * page 3 *;
 [P]EP2319849  (STELLA PHARMA CORP [JP])
 [Y]  - RAJIV R. SRIVASTAVA, ET AL., "Synthesis of 1-Amino-3-[2-(1,7-dicarba-closo-dodecaboran(12)-1-yl)ethyl]cyclobutanecarboxylic Acid: A Potential BNCT Agent", JOURNAL OF ORGANIC CHEMISTRY, (1997), vol. 62, pages 4476 - 4478, XP002715796 [Y] 1-6 * page 4477; compound 1 *

DOI:   http://dx.doi.org/10.1021/jo970148+
International search[Y]WO2010010912  (STELLA PHARMA CORP [JP], et al);
 [Y]WO9809973  (UNIV TENNESSEE RES CORP [US]);
 [A]WO2010010913  (STELLA PHARMA CORP [JP], et al)
by applicant   - I. M. WYZLIC ET AL., TETRAHEDRON LETT., (1992), vol. 33, pages 7489 - 7490
    - W. TJARK, J. ORGANOMET. CHEM., (2000), pages 614 - 615,37-47
    - K. IMAMURA ET AL., BULL. CHEM. SOC. JPN., (1997), vol. 70, pages 3103 - 3110
    - A. S. AL-MADHORN ET AL., J. MED. CHEM., (2002), vol. 45, pages 4018 - 4028
    - F. COMPOSTELLA ET AL., RES. DEVELOP. NEUTRON CAPTURE THER., (2002), pages 81 - 84
    - J. CAI ET AL., J. MED. CHEM., (1997), vol. 40, pages 3887 - 3896
    - H. LIM ET AL., RES. DEVELOP. NEUTRON CAPTURE THER., (2002), pages 37 - 42
    - GABEL, D.; MOLLER, D.; HARFST, S.; ROSLER, J.; KETZ, H., INORG. CHEM., (1993), vol. 32, pages 2276 - 2278
    - REMINGTON'S PHARMACEUTICAL SCIENCES, MAACK PUBLISHING CO.
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.